- Home
- GXO vs IONS Comparison
GXO vs IONS Comparison
Compare GXO & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXO
- IONS
- Stock Information
- Founded
- GXO 2021
- IONS 1989
- Country
- GXO United States
- IONS United States
- Employees
- GXO N/A
- IONS N/A
- Industry
- GXO Transportation Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- GXO Consumer Discretionary
- IONS Health Care
- Exchange
- GXO Nasdaq
- IONS Nasdaq
- Market Cap
- GXO 4.8B
- IONS 4.6B
- IPO Year
- GXO N/A
- IONS 1991
- Fundamental
- Price
- GXO $39.68
- IONS $32.55
- Analyst Decision
- GXO Buy
- IONS Buy
- Analyst Count
- GXO 13
- IONS 18
- Target Price
- GXO $55.31
- IONS $57.41
- AVG Volume (30 Days)
- GXO 1.3M
- IONS 1.7M
- Earning Date
- GXO 05-07-2025
- IONS 04-30-2025
- Dividend Yield
- GXO N/A
- IONS N/A
- EPS Growth
- GXO N/A
- IONS N/A
- EPS
- GXO 0.62
- IONS N/A
- Revenue
- GXO $12,230,000,000.00
- IONS $717,253,000.00
- Revenue This Year
- GXO $8.34
- IONS N/A
- Revenue Next Year
- GXO $6.07
- IONS $27.39
- P/E Ratio
- GXO $63.54
- IONS N/A
- Revenue Growth
- GXO 23.40
- IONS N/A
- 52 Week Low
- GXO $30.46
- IONS $23.95
- 52 Week High
- GXO $63.33
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- GXO 61.88
- IONS 62.08
- Support Level
- GXO $36.75
- IONS $31.66
- Resistance Level
- GXO $41.12
- IONS $33.98
- Average True Range (ATR)
- GXO 1.16
- IONS 1.27
- MACD
- GXO 0.63
- IONS 0.47
- Stochastic Oscillator
- GXO 76.35
- IONS 85.51
About GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.